Bioventus (BVS) Total Liabilities (2020 - 2026)

Bioventus' Total Liabilities history runs 7 years deep, the most recent figure standing at $416.3 million for Q1 2026.

• Quarterly Total Liabilities fell 17.72% year-over-year to $416.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $416.3 million (down 17.72% YoY) and the FY2025 annual result came in at $455.1 million, down 16.09% from the prior year.
• Total Liabilities was $416.3 million for Q1 2026 at Bioventus, down from $455.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $1.0 billion in Q4 2022 and bottomed at $416.3 million in Q1 2026.
• A 5-year average of $614.7 million and a median of $584.6 million in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities soared 140.14% — and 2023, when it plunged 42.62%.
• Bioventus' Total Liabilities stood at $960.4 million in 2022, then plunged by 38.59% to $589.8 million in 2023, then slipped by 8.04% to $542.4 million in 2024, then fell by 16.09% to $455.1 million in 2025, then slipped by 8.53% to $416.3 million in 2026.
• Business Quant data shows BVS's Total Liabilities at $416.3 million in Q1 2026, $455.1 million in Q4 2025, and $494.3 million in Q3 2025.